Therapy Directory

Bevacizumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Bevacizumab as a study intervention. Browse Bevacizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 3:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1372

Shown on this page

Current sort

Live official records

Open in full search

Conditions: PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
Interventions: HWK-016, MUCIN-16-targeted ADC, Bevacizumab; Drug
Lead sponsor: Whitehawk Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Little Rock, Arkansas • Los Angeles, California • Sarasota, Florida + 9 more

Conditions: Colorectal Cancer, CRC
Interventions: Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Advanced Cholangiocarcinoma, FGFR2 Fusion
Interventions: Pemigatinib, Atezolizumab, Bevacizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions: Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Durvalumab, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy, Tremelimumab; Biological · Procedure · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 138
States / cities: Berkeley, California • Cameron Park, California • Fremont, California + 108 more

Conditions: Advanced Solid Tumors
Interventions: ASP1570, pembrolizumab, Trifluridine + Tipiracil, Bevacizumab, Docetaxel, Oxaliplatin, Leucovorin, 5-Fluorouracil, Irinotecan, Pemetrexed, Carboplatin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 12
States / cities: Fullerton, California • Los Angeles, California • Sarasota, Florida + 8 more

Conditions: Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
Interventions: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration; Biological · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Buffalo, New York • Houston, Texas

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
Interventions: GTAEXS617, SoC; Drug
Lead sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more

Conditions: Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
Interventions: MRG007, MRG007 and Bevacizumab; Drug
Lead sponsor: ArriVent BioPharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
Interventions: Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Osimertinib; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 18
States / cities: Los Angeles, California • Pasadena, California • Sacramento, California + 11 more

Conditions: Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer
Interventions: Atezolizumab, Bevacizumab, Biospecimen Collection, Cisplatin, Computed Tomography, Conventional Magnetic Resonance Imaging, Gemcitabine Hydrochloride; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 37
States / cities: Auburn, California • Berkeley, California • Fremont, California + 27 more

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IVB Cervical Cancer American Joint Committee on Cancer (AJCC) v8
Interventions: Bevacizumab, Biospecimen Collection, Brachytherapy, Cisplatin, External Beam Radiation Therapy, Paclitaxel, Pembrolizumab, Questionnaire Administration; Biological · Procedure · Radiation + 2 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: Los Angeles, California • San Diego, California • Oklahoma City, Oklahoma + 1 more

Conditions: Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Bevacizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Houston, Texas

About this Bevacizumab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Bevacizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Bevacizumab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Bevacizumab clinical trials

Filter and sort this therapy

Live official records

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer

Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

About this Bevacizumab clinical trials directory page